One might surmise that by the time FDA asks an advisory committee to vet an application, the questions would deal primarily with clinical utility.
Love them or hate them, site visits have been a part of the culture of NCI-designated cancer centers for decades, shaping the process for admitting members to the elite club and influencing internal politics within institutions.
